NBY

NovaBay Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $850.57M and approximately 13 employees. The company's industry classification is biotechnology. Financial health for NovaBay indicates a challenging situation, with significant net losses (TTM: -$6,985,000) and negative EBITDA (-$5,103,000). Profitability margins are also concerning, with an operating margin of -224.4% and a profit margin of 31.5%. Balance sheet metrics reveal substantial cash reserves ($2.31M), but high debt levels ($970,000) result in a debt to equity ratio of 59.36. Valuation metrics for NovaBay are predominantly negative, with a P/E ratio (TTM) of 1.31 and forward P/E of -8.23. The price to book value is also negative (-15.13). Revenue growth has been substantial in the past year, but at a loss (-78.7% YoY), while earnings growth data is not available.